文献速递类风湿关节炎

ACPA与RF对类风湿关节炎持续临床缓解的预测作用:OBRI登记研究数据

ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI).
PubMed 文献 · RMD Open · 2018-11-05

该研究基于加拿大安大略省最佳实践研究倡议(OBRI)登记队列,纳入970例有≥1个肿胀关节且具备自身抗体信息的类风湿关节炎(RA)患者,评估ACPA与RF联合状态对持续临床缓解的预测作用。中位随访约3年,ACPA阳性/RF阳性患者持续缓解率最高(43.5%),且较ACPA阴性/RF阴性患者更快达到持续缓解(HR 1.30;95%CI 1.01-1.67)。结论提示ACPA与RF联合阳性与更优、更快的抗风湿药物应答相关。

要点

  • ACPA阳性/RF阳性患者持续缓解率43.5%,高于双阴性患者的32.4%(p=0.01)。
  • ACPA阳性/RF阳性较双阴性患者更快达到持续缓解(HR 1.30;95%CI 1.01-1.67)。
  • ACPA阳性患者年龄更轻、疾病活动度和残疾程度更低(组间差异显著)。

核心结论

  • ACPA与RF联合阳性与RA患者对抗风湿药物更优且更快的应答相关。

研究设计与样本

  • 基于安大略最佳实践研究倡议(OBRI)登记队列的观察性研究,纳入970例有≥1个肿胀关节、具备自身抗体信息且≥1次随访评估的RA患者。
  • 持续临床缓解定义为至少两次连续访视(间隔3-12个月)CDAI≤2.8。
  • 采用累积发病率曲线和多变量Cox回归评估达到持续缓解的时间。

主要发现

  • 970例纳入患者中,ACPA阴性/RF阴性262例(27%),ACPA阳性/RF阴性60例(6.2%),ACPA阴性/RF阳性117例(12.1%),ACPA阳性/RF阳性531例(54.7%)。
  • 组间在年龄(p=0.02)、CDAI(p=0.03)、压痛关节数(p=0.02)和HAQ(p=0.002)方面差异显著,ACPA阳性患者最年轻且疾病活动度和残疾程度最低。
  • 组间生物制剂使用无差异(20.2%患者使用)。
  • 平均随访3年,持续缓解率分别为ACPA阳性/RF阳性43.5%、ACPA阳性/RF阴性43.3%、ACPA阴性/RF阳性31.6%、ACPA阴性/RF阴性32.4%(p=0.01)。
  • ACPA阳性/RF阳性较ACPA阴性/RF阴性患者达到持续缓解时间更短(HR 1.30;95%CI 1.01-1.67),CDAI改善显著更高。

关键数值与推荐

  • 持续临床缓解:CDAI≤2.8,至少两次连续访视间隔3-12个月。

临床怎么用

  • 基线ACPA和RF联合状态可用于预判RA患者达到持续临床缓解的可能性和速度。
  • ACPA阳性/RF阳性患者可能更快达到持续缓解,可据此与患者沟通治疗预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study evaluated the interaction of anticitrullinated protein antibody (ACPA) and rheumatoid factor (RF) in predicting sustained clinical response in an observational registry of patients with rheumatoid arthritis (RA) followed in routine practice. METHODS: Patients with RA enrolled in the Ontario Best Practices Research Initiative registry, with ≥1 swollen joint, autoantibody information and ≥1 follow-up assessment were included. Sustained clinical remission was defined as Clinical Disease Activity Index (CDAI) ≤2.8 in at least two sequential visits separated by 3-12 months. Time to sustained remission was assessed using cumulative incidence curves and multivariate cox regression. RESULTS: Among 3251 patients in the registry, 970 were included, of whom 262 (27%) were ACPAneg/RFneg, 60 (6.2%) ACPApos /RFneg, 117 (12.1%) ACPAneg/RFpos and 531 (54.7%) ACPApos /RFpos at baseline. Significant between group differences were observed in age (p=0.02), CDAI (p=0.03), tender joint count (p=0.02) and Health Assessment Questionnaire (p=0.002), with ACPApos patients being youngest with lowest disease activity and disability. No difference in biologic use was found between groups (20.2% of patients).Over a mean follow-up of 3 years, sustained remission was achieved by 43.5% of ACPApos/RFpos patients, 43.3% of ACPApos /RFneg patients, 31.6 % of ACPAneg/RFpos patients and 32.4% of ACPAneg/RFneg patients (p=0.01). Significant differences were observed in CDAI improvement based on ACPA and RF status where ACPApos/RFpos had a shorter time to achieving sustained remission (HR 1.30; 95% CI 1.01 to 1.67) and experienced significantly higher improvements compared with ACPAneg/RFneg patients. CONCLUSIONS: Combined ACPA and RF positivity were associated with improved and faster response to antirheumatic medications in patients with RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Pope JE, Movahedi M, Rampakakis E, et al. ACPA and RF as predictors of sustained clinical remission in patients with rheumatoid arthritis: data from the Ontario Best practices Research Initiative (OBRI). RMD Open. 2018. PMID: 30487995. doi:10.1136/rmdopen-2018-000738

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。